Faron Pharma expands bexmarilimab programme in solid tumours with a randomized phase I/II BEXAR IIT in metastatic soft-tissue sarcoma: Turku, Finland Thursday, January 29, 2026, 1 ...

Alphamab Oncology (Stock Code: 9966.HK) announced that the results from a phase III clinical study for the treatment of HER2-positive gastric or gastroesophageal junction cancer (GC/GEJ) of ...

JAMA Dermatology recently published the results of a Phase II study of novel TYK2 inhibitor soficitinib (ICP-332) in patients with moderate-to-severe atopic dermatitis (AD). The journal concluded that ...

The study evaluates how omega-3 delivery architecture influences triglyceride outcomes and omega-3 incorporation in ...

Study conducted in a collaboration between MEDSIR and University Hospital Vall d'Hebron to evaluate bexmarilimab plus standard-of-care doxorubicin in a high-unmet-need frontline setting. TURKU, FI / ...

The U.S. is giving $1.6 million to researchers to study how the hepatitis B vaccine affects newborns in Guinea-Bissau. Local ...

Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced positive topline results from its randomized, ...

More than 135 million American adults are either living with or at risk for type 2 diabetes (T2D), elevating the need for ...

A new randomized clinical trial has revealed that just 24 minutes of listening to specially designed music paired with ...